Title:
ＦＧＦＲ３阻害剤化合物
Document Type and Number:
Japanese Patent JP2023554598
Kind Code:
A
Abstract:
本発明は、全身性硬化症、線維症（例えば、肺線維症）、軟骨無形成症、致死性骨異形成症（例えば、Ｉ型）、発育遅延及び黒色表皮腫を伴う重度の軟骨無形成症（ＳＡＤＤＡＮ）、ムエンケ症候群、又はがんの治療に使用するための、以下の式の化合物を提供する。TIFF2023554598000542.tif4196
Inventors:
Abraham, Adedoyin David
Bume, Desta d'Oro
Kondroski, Kevin Ronald
Dilger, Andrew Carl
hazlitt, robert allan
kercher, timothy scott
Metcalfe, Andrew Terrance
Urukaran, Kaveri Balan
Walls, Shane Michael
Bume, Desta d'Oro
Kondroski, Kevin Ronald
Dilger, Andrew Carl
hazlitt, robert allan
kercher, timothy scott
Metcalfe, Andrew Terrance
Urukaran, Kaveri Balan
Walls, Shane Michael
Application Number:
JP2023530844A
Publication Date:
December 28, 2023
Filing Date:
March 03, 2022
Export Citation:
Assignee:
Eli Lilly and Company
International Classes:
C07D471/04; A61K31/4545; A61K31/496; A61K31/497; A61K31/501; A61K31/55; A61P11/00; A61P19/00; A61P25/00; A61P35/00; A61P43/00; C07D519/00
Attorney, Agent or Firm:
Norito Yamao
Nagatoshi Shinagawa
Wu Yingyan
Nagatoshi Shinagawa
Wu Yingyan
Previous Patent: Cyclobenzaprine treatment for alcohol use disorder
Next Patent: Fuel cell membrane humidifier and fuel cell system including the same
Next Patent: Fuel cell membrane humidifier and fuel cell system including the same